Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA8KQR)

Drug Name
GB0139 Drug Info
Synonyms
TD139; TD-139; 1450824-22-2; olitigaltin; TD 139; GB0139; GB-0139; Olitigaltin [USAN]; 60Y0GUO72B; 3-Deoxy-3-[4-(3-Fluorophenyl)-1h-1,2,3-Triazol-1-Yl]-Beta-D-Galactopyranosyl 3-Deoxy-3-[4-(3-Fluorophenyl)-1h-1,2,3-Triazol-1-Yl]-1-Thio-Beta-D-Galactopyranoside; (2R,2'R,3R,3'R,4S,4'S,5R,5'R,6S,6'S)-6,6'-Thiobis(4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol); (2S,3R,4S,5R,6R)-4-[4-(3-Fluorophenyl)triazol-1-yl]-2-[(2S,3R,4S,5R,6R)-4-[4-(3-fluorophenyl)triazol-1-yl]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl-6-(hydroxymethyl)oxane-3,5-diol; UNII-60Y0GUO72B; TD2; OLITIGALTIN [INN]; Gal-3 Inhibitor GB0139; Galectin-3 Inhibitor GB0139; CHEMBL4297442; SCHEMBL15657269; TD 139 [WHO-DD]; GTPL12148; EX-A1688; BDBM50581762; WHO 12032; AKOS027325618; CS-6265; DB12895; GB 0139; AC-35516; beta-D-Galactopyranoside, 3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-beta-D-galactopyranosyl 3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-1-thio-; BS-15429; BT173009; HY-19940; C72753; A857944; Q27263259; bis-(3-deoxy-3-(3-fluorophenyl-1h-1,2,3-triazol-1-yl)-beta-d-galactopyranosyl)-sulfane; .BETA.-D-GALACTOPYRANOSIDE, 3-DEOXY-3-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-.BETA.-D-GALACTOPYRANOSYL 3-DEOXY-3-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-1-THIO-; 3,3'-DIDEOXY-3,3'-BIS-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-1,1'-SULFANEDIYL-DI-.BETA.- D-GALACTOPYRANOSIDE; BIS(3-DEOXY-3-(3-FLUOROPHENYL-1H-1,2,3-TRIAZOL-1-YL)-.BETA.-D-GALACTOPYRANOSYL)SULFANE
Indication
Disease Entry ICD 11 Status REF
Idiopathic pulmonary fibrosis CB03.4 Phase 2 [1]
Cross-matching ID
PubChem CID
73774610
TTD Drug ID
DMA8KQR

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Galectin-3 (LGALS3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GR-MD-02 DM9QF65 Hypertension BA00-BA04 Phase 2 [3]
PFFFFF DM9AZKE Discovery agent N.A. Investigative [4]
2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide DM592YS Discovery agent N.A. Investigative [5]
GR-MD-02 DM9QF65 Hypertension BA00-BA04 Phase 2 [3]
PFFFFF DM9AZKE Discovery agent N.A. Investigative [4]
2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide DM592YS Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Galectin-3 (LGALS3) TTFPQV7 LEG3_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03832946) GALACTIC-1 -A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of GB0139, an Inhaled Galectin-3 Inhibitor Administered Via a Dry Powder Inhaler Over 52 Weeks. U.S.National Institutes of Health.
2 An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE). Am J Respir Crit Care Med. 2023 Jan 15;207(2):138-149.
3 Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013 Dec 18;8(12):e83481.
4 Discovery of galectin ligands in fully randomized combinatorial one-bead-one-compound (glyco)peptide libraries. Bioorg Med Chem Lett. 2007 Feb 1;17(3):793-8.
5 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.